RE:RE:RE:RE:RE:Turkey's population is over is 84 millionI do not understand at any level how you came to that understanding. MedX gets paid (revenue) from the moment they commence a pilot/trial. They do not donate the hardware they get paid (revenue) they get paid per consult (scan fee) so if they are running numerous trials globally then every trial is contributing revenue immediately. As trials/pilots prove to be valuable then they would naturally convert to more locations being deployed and more revenue being added.
It goes back to my earlier post that MedX gave guidance they were now commencing a number of trials that would allow investors to see revenue traction and be able to get some understanding of the potential revenue from each pilot/trial site.
If you go back to the Italian announcement it is laid out there;
Europe continues to be a strong focus of MedX’s global commercialization strategy, following the ongoing success of its pilot program in the Netherlands. The MedX and Vitamed pilot program in Italy is expected to be in-market for 60 days from October to November 2021. Pending its successful completion, the MedX DermSecure® Screening Platform will become more widely available at pharmacies, GP clinics and insurance companies across Italy, as the next step in the commercialization strategy in this market. MedX will continue to build on this momentum with additional pilots anticipated later this year.